TY - JOUR
T1 - Fatty acid monooxygenation by P450BM-3
T2 - Product identification and proposed mechanisms for the sequential hydroxylation reactions
AU - Boddupalli, Sekhar S.
AU - Pramanik, Bikash C.
AU - Slaughter, Clive A.
AU - Estabrook, Ronald W.
AU - Peterson, Julian A.
N1 - Funding Information:
’ This work was supported in part by research Grants GM 19036 and GM 43479 (to J.A.P.) and GM 16488 (to R.W.E.) from the National Institutes of Health and by research Grants I-0405 (to J.A.P.) and I-0959 (to R.W.E.) from the Robert A. Welch Foundation. ’ To whom correspondence should be addressed.
PY - 1992/1
Y1 - 1992/1
N2 - The soluble P450 isolated from Bacillus megaterium (the product of the CYP102 gene) (P450BM-3) is a catalytically self-sufficient fatty acid hydroxylase which converts lauric, myristic, and palmitic acids to ω-1, ω-2, and ω-3 hydroxy analogs. The percentage distribution of the regioisomers depends on the substrate chain length. Lauric and myristic acids were preferentially metabolized to their ω-1 hydroxy counterparts while no hydroxylation occurred when capric acid was used as the substrate. Palmitic acid, when present at concentrations greater than the concentration of oxygen in the reaction medium (>250 μm), was hydroxylated to its ω-1, ω-2, and ω-3 hydroxy analogs, with the percentage distribution of the regioisomers being 21:44:35, respectively. No ω hydroxylation of any of the fatty acids was detected. When the concentration of palmitic acid was less than the concentration of oxygen in the reaction mixture, it was noted that a number of additional products were formed. Under these conditions, unlike lauric and myristic acids, it was observed that palmitic acid was first converted to its monohydroxy isomers which were subsequently metabolized to a mixture of 14-ketohexadecanoic, 15-ketohexadecanoic, 13-hydroxy-14-ketohexadecanoic, 14-hydroxy-15-ketohexadecanoic, and 13,14-dihydroxyhexadecanoic acids with a relative distribution of 8:2:40:30:20, respectively. Thus, P450BM-3 is able not only to monohydroxylate a variety of fatty acids but also to further metabolize some of these primary metabolites to secondary and tertiary products. The present paper characterizes the products formed during the sequential hydroxylation of palmitic acid and proposes reaction pathways to explain these results.
AB - The soluble P450 isolated from Bacillus megaterium (the product of the CYP102 gene) (P450BM-3) is a catalytically self-sufficient fatty acid hydroxylase which converts lauric, myristic, and palmitic acids to ω-1, ω-2, and ω-3 hydroxy analogs. The percentage distribution of the regioisomers depends on the substrate chain length. Lauric and myristic acids were preferentially metabolized to their ω-1 hydroxy counterparts while no hydroxylation occurred when capric acid was used as the substrate. Palmitic acid, when present at concentrations greater than the concentration of oxygen in the reaction medium (>250 μm), was hydroxylated to its ω-1, ω-2, and ω-3 hydroxy analogs, with the percentage distribution of the regioisomers being 21:44:35, respectively. No ω hydroxylation of any of the fatty acids was detected. When the concentration of palmitic acid was less than the concentration of oxygen in the reaction mixture, it was noted that a number of additional products were formed. Under these conditions, unlike lauric and myristic acids, it was observed that palmitic acid was first converted to its monohydroxy isomers which were subsequently metabolized to a mixture of 14-ketohexadecanoic, 15-ketohexadecanoic, 13-hydroxy-14-ketohexadecanoic, 14-hydroxy-15-ketohexadecanoic, and 13,14-dihydroxyhexadecanoic acids with a relative distribution of 8:2:40:30:20, respectively. Thus, P450BM-3 is able not only to monohydroxylate a variety of fatty acids but also to further metabolize some of these primary metabolites to secondary and tertiary products. The present paper characterizes the products formed during the sequential hydroxylation of palmitic acid and proposes reaction pathways to explain these results.
UR - http://www.scopus.com/inward/record.url?scp=0026565605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026565605&partnerID=8YFLogxK
U2 - 10.1016/0003-9861(92)90045-X
DO - 10.1016/0003-9861(92)90045-X
M3 - Article
C2 - 1727637
AN - SCOPUS:0026565605
SN - 0003-9861
VL - 292
SP - 20
EP - 28
JO - Archives of Biochemistry and Biophysics
JF - Archives of Biochemistry and Biophysics
IS - 1
ER -